These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15728914)

  • 1. Alpha interferon and ribavirin combination therapy of chronic hepatitis D.
    Kaymakoglu S; Karaca C; Demir K; Poturoglu S; Danalioglu A; Badur S; Bozaci M; Besisik F; Cakaloglu Y; Okten A
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1135-8. PubMed ID: 15728914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis.
    Gunsar F; Akarca US; Ersoz G; Kobak AC; Karasu Z; Yuce G; Ilter T; Batur Y
    Antivir Ther; 2005; 10(6):721-6. PubMed ID: 16218171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
    Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
    Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy.
    Saracco G; Olivero A; Ciancio A; Carenzi S; Smedile A; Cariti G; Andreoni M; Orsi PG; Biglino A; Tabone M; Roffi L; Croce G; Manca A; Tappero G; Ciccone G; Rizzetto M
    Hepatology; 2002 Oct; 36(4 Pt 1):959-66. PubMed ID: 12297844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
    Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
    Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
    Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V
    Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
    Min AD; Jones JL; Esposito S; Lebovics E; Jacobson IM; Klion FM; Goldman IS; Geders JM; Tobias H; Bodian C; Bodenheimer HC
    Am J Gastroenterol; 2001 Apr; 96(4):1143-9. PubMed ID: 11316161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Why is there a poor response to combined therapy with interferon alfa 2b and ribavirin in patients with chronic hepatitis C?].
    Stránský J; Rýzlová M; Stríteský J; Nĕmecek V
    Cas Lek Cesk; 2002 Jun; 141(11):351-4. PubMed ID: 12099059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C.
    Furusyo N; Kubo N; Toyoda K; Takeoka H; Nabeshima S; Murata M; Nakamuta M; Hayashi J
    Antiviral Res; 2005 Jul; 67(1):46-54. PubMed ID: 15913800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3].
    Cornberg M; Hüppe D; Wiegand J; Felten G; Wedemeyer H; Manns MP
    Z Gastroenterol; 2003 Jun; 41(6):517-22. PubMed ID: 12806536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
    Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
    J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy.
    Tromm A; Greving I; Griga T; Mankel K; Hüppe D
    Z Gastroenterol; 2000 Feb; 38(2):159-64. PubMed ID: 10721171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C.
    Hoffmann RM; Berg T; Teuber G; Prümmer O; Leifeld L; Jung MC; Spengler U; Zeuzem S; Hopf U; Pape GR
    Z Gastroenterol; 1999 Aug; 37(8):715-23. PubMed ID: 10494606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].
    Lee HJ; Eun JR; Choi JW; Kim KO; Moon HJ
    Korean J Hepatol; 2008 Mar; 14(1):46-57. PubMed ID: 18367857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C.
    Shakil AO; McGuire B; Crippin J; Teperman L; Demetris AJ; Conjeevaram H; Gish R; Kwo P; Balan V; Wright TL; Brass C; Rakela J
    Hepatology; 2002 Nov; 36(5):1253-8. PubMed ID: 12395337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
    Bizollon T; Palazzo U; Ducerf C; Chevallier M; Elliott M; Baulieux J; Pouyet M; Trepo C
    Hepatology; 1997 Aug; 26(2):500-4. PubMed ID: 9252166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study.
    Alberti AB; Belli LS; Airoldi A; de Carlis L; Rondinara G; Minola E; Vangeli M; Cernuschi A; D'Amico M; Forti D; Pinzello G
    Liver Transpl; 2001 Oct; 7(10):870-6. PubMed ID: 11679985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.